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CASE R E P O R T
Pseudoporphyria due to Naproxen
A cluster of 3 cases
M.C.W. Creemers1, A. Chang2, M.J.A.M. Franssen3, T.J.W. Fiselier4, and P.L.C.M. van Riel1
j
Depts. rheumatology1, dermatology2 and pediatric rheumatology3 University Hospital Nijmegen, St. Radboud and dept. rheumatology 
St. Maartenshospital Nijmegen4, the Netherlands.
Pseudoporphyria is a photo-induced blistering disorder with increased skin fragility, caused among others by nonsteroidal antiinflammatory 
drugs. Lesions heal with scarring and milia. Porphyrin screen studies are normal in this disease. Histology and immunofluorescence resembles 
porphyria cutanea tarda. In this report we describe a cluster of three cases of naproxen-induced pseudoporphyria, and review briefly 
previously reported cases induced by naproxen. The majority of reported cases involve children. Physicans should be aware of this reversible 
skin disorder.
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Pseudoporphyria is a blistering disorder with increased  
skin fragility. It resem bles porphyria cutanea taiJda 
(PCT) in its5 reaction to the intake o f certain drugs and 
sunlight exposure, but without disorders in the porphy­
rin metabolism. O nly sunlight exposed areas o f  the 
skin are involved; face, dorsal surfaces o f  hands and 
feet and less often the neck except the area underneath 
the chin and behind the ears. Usually blisters heal with  
scarring and m ilia. Blisters are subepidermal and his-
»tology is identical to abnormalities found in PCT. PCT  
patients lack uroporphyrinogen decarboxylase, an en­
zyme of the hem e biosynthesis, by contrast in pseudo- 
porphyria porphyrin screen in erythrocytes, urine and 
feces is normal. Pseudoporphyria due to naproxen was 
believed to be a rare adverse reaction to the drug, 
although by now a hundred cases have been reported.
We report here three cases o f  pseudoporphyria due 
to naproxen and review  briefly the literature, the estab­
lishment o f  diagnosis and hypothetical m echanism s.
Cases
Case 1
During holidays at the Canary Islands a 42-year-old  
white woman experienced blistering and skin fragility 
of the dorsa o f  both hands, fingers and feet for 8 w eeks. 
Her medical history included a m oderately active an­
kylosing spondylitis and in the past a pityriasis rosea. 
She had been taking an oral contraceptive for several 
years and naproxen 500 m g b i.d . for 8 months. Earlier
she had used other N S A ID s. There w as no history o f  
hepatitis, porphyria or other photosensitivity disorders. 
Exam ination o f  the skin revealed sm all blisters with  
slight scarring from old lesions. N o  hyperpigm enta­
tion, hirsutism , milia or atrophic scarring were present. 
Laboratory exam ination, repeated tw ice, revealed nor­
mal liverfunction tests and a normal porphyrin screen  
in erythrocytes, urine and feces w as demonstrated  
tw ice. Peri lesionai skin biopsies show ed subepidermal 
bullae formation. D irect im m unofluorescence o f  the 
perilesional skin show ed  aspecific condensation o f  
IgM  and C3 at the edge o f  the bulla. IgG , fibrinogen, 
IgA  and C )q were diffusely deposited in the dermal 
layer. N o  signs o f  bullous pem phigoid  w ere present. 
Naproxen w as discontinued , but new  lesions occurred  
for another 8 w eek s, thereafter blistering ceased with  
minimal scarring.
M.C.W. Creemers, P.O. Box 9101, NL-6500 HB Nijmegen, The 
Netherlands
Received 5 April 1994 
Accepted 12 October 1994
Case 2
A  58-year-old  white man, w ho had used sunbeds regu­
larly for several years, had a 6 -w eek  history o f  blister­
ing and skin fragility o f  the dorsa o f  both hands. His 
m edical history com prised a longstanding, m oderately  
active, ankylosing spondylitis, for which he took  
N SA ID s for many years, and prostatism , without hepa­
titis, porphyria or photosensitivity disorders. The pa-
4tient reported that he had experienced the sam e lesions  
about 5 to 6 years earlier, but to a lesser extent and 
degree. On both occasions he was using naproxen 500  
m g b.i.d. Exam ination o f  the skin show ed  sm all blisters 
and som e old  lesions with slight scarring. N o other 
abnormalities o f the skin were seen . Liverfunction  
tests, porphyrin screen in erythrocytes and urine re­
vealed normal. Skin biopsies were not conclusive be-
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cause o f  a sampling error. He decided to continue 
naproxen because o f good efficacy, despite advise to 
stop, and started to use a sunfilter when using sunbeds. 
Skin lesions healed with scarring within a few weeks. 
Almost 1.5 years later, no new skin lesions occurred 
despite naproxen use, but slight skin fragility re­
mained.
Case 3
A 9-year-old white girl with polyarticular systemic- 
onset juvenile chronic arthritis revealed blistering and 
skin fragility of the face and dorsa of both hands, 
aggravated by sunlight exposure. She had no history of 
hepatitis, porphyria or photosensitivity disorders. She 
was taking methotrexate 10 mg weekly and naproxen 
250 mg b.i.d. (20 mg/kg/day), She had not been treated 
before with other NSAIDs. Skin examination showed 
blistering with crustae and scarring of old lesions. 
Liverfunction tests were normal. A skin biopsy was not 
felt to be justifiable in view of the age of the patient 
and the site of the blistering. After naproxen was 
changed into diclofenac, no new blistering occurred 
and lesions healed within several weeks.
Discussion
Though other nonsteroidal antiinflammatory drugs
p(NSAIDs) are known to cause pseudoporphyria as 
well, the majority of cases published were caused by 
naproxen (1-9).
A total of 100 cases of pseudoporphyria due to 
naproxen are known, remarkably 74 of these were 
children. The mean age of children was 7 years (range 
1-18 years) and in adults age ranged from 21 to 84 
years. In adults it appeared that mostly women were 
involved (14 women versus 7 men, 5 not reported), in 
most cases involving children sex was not reported. 
Most cases manifested itself during summer, not al­
ways clearly related to sunlight exposure, 3 cases oc­
curred after visiting a solarium. Dose of naproxen in 
adults was 250 to 1500 mg/day, in children the mean 
dose was 13 mg/kg/day, and the use of naproxen 
ranged from a few weeks to several years before onset 
o f pseudoporphyria. Most frequently lesions occurred 
on the dorsal surfaces of hands and feet, in some cases 
in the face, in a few cases on the neck and in one case 
also on both knees. Scarring usually remained after 
healing but showed a tendency to fade. Porphyrin 
screening was done in the majority of cases and re­
vealed normal, Histology was reported in 16 cases and 
in 11 o f  these 19 biopsies, immunofluorescence was 
done, all biopsies were conclusive for PCT-like ab­
normalities. Naproxen was stopped in all patients after 
which skin lesions healed. In 14 cases the time needed
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for healing was described and was on average 5 weeks 
(range 1 week to 2 months).
All three cases described here manifested itself in 
the summer o f 1992, which was an ordinary Dutch 
summer, though one case manifested itself at the 
Canary Islands. Pseudoporphyria due to naproxen was 
not seen earlier at our clinics. Our two adults took part 
in a 48-week double-blind study comparing ß-cyclo- 
dextrin-piroxicam (n = 30) with naproxen (n = 29) in 
ankylosing spondylitis. One o f our-cases (case 2) dif­
fers from other cases in the literature as skin lesions 
healed while naproxen was still being administered, 
but patient had started to use a sunfilter. One case of 
pseudoporphyria due to nalidix acid behaved similarly 
(10). No porphyrin screen was done in case 3, but the 
causal relation with discontinuation o f naproxen and 
subsiding of characteristic skin lesions confirm the 
diagnosis.
Although phototoxicity is w idely accepted, several 
hypotheses have been developed. Naproxen is known 
to stabilize the liposomal membrane in vitro and to be a 
potent inhibitor of cyclo-oxygenase. In most hypothe­
ses sunlight plays a central role. The inflammation of 
the sun exposed skin may be due to: a. the chemical 
structure of NSAIDs itself which may induce photo- 
sensitation of the skin (4, 11); b. the release o f free 
oxygen radicals by naproxen which may contribute to 
the phototoxic reaction (4, 8), probably as well aggra­
vated by complement compounds (7). Other hypoth­
eses suggest that pseudoporphyria patients have minor 
disturbances o f heme-biosynthesis leading to symp­
toms in case of excessive sunlight exposure (5, 12), 
perhaps sometimes associated with intake o f alcohol 
(5), estrogens (5) or eventually minor skin trauma (6). 
The relation with sunlight exposure is confirmed espe­
cially in three patients with vitiligo in whom bullae 
were only present on areas o f vitiligo (12-14). Not 
only exposure to a high intensity o f  sunlight may 
induce pseudoporphyria, but also multiple prolonged 
low-grade exposure may cause skin lesion resulting 
mostly in decreased adhesion o f dermis and epidermis
(9, 15).
It is not easy to explain the larger frequency of 
pseudoporphyria due to naproxen in children (Allen et 
al. (6) even reported that 6% o f  ail children using 
naproxen experienced pseudoporphyria), especially as 
far less children than adults use naproxen. Possibly 
children experience more frequently trauma of the skin 
during sunlight exposure and are more exposed.
Pseudopoiphyria might be seen as a ‘diagnosis per 
exclusionen*. PCT, epidermolysis bullosa acquisita and 
hydroa vacciniforme must first be ruled out as a diag­
nosis. The-only difference between PCT and pseudo­
porphyria is the negative porphyrin screen in the latter.
It may be concluded that the pathogenesis o f pseu­
dopoiphyria due to naproxen is still not clear, but there 
seems to be a relation to sunlight exposure and perhaps
Pseiidoporphyria due to naproxen
minor skin trauma. Discontinuation o f naproxen is the 
best treatment. One should be aware o f this adverse 
drug reaction, especially in fair skinned patients and 
even more in children.
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